In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.
Breast Cancer Targets
Adding ribociclib, a CDK4/6 inhibitor, to letrozole significantly improved progression-free survival in postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.
OPT-822/821 vaccination did not show any improvement in progression-free survival as maintenance therapy compared with placebo for metastatic breast cancer. But in those patients who had an immune response, the vaccine did appear to show activity.
Heavily pretreated women with metastatic breast cancer had significant improvements in progression-free survival and overall response rate when treated with the combination of utidelone plus capecitabine compared with capecitabine alone.
The investigational biosimilar MYL-1401O has comparable efficacy and safety to the FDA-approved trastuzumab in metastatic HER2-positive breast cancer.
In this interview we discuss research into cancer vaccines and checkpoint inhibitors for the treatment of breast cancer.
ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.
T-DM1 improved survival in women with HER2-positive breast cancer, even after treatment with two or more other HER2-targeted therapies including trastuzumab and lapatinib.
Women with advanced endocrine-resistant breast cancer who had PIK3CA mutations in their circulating tumor DNA had an almost 4-month progression-free survival improvement when adding the PIK3CA inhibitor buparlisib to fulvestrant.
Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.